P

Perceptive

Imaging core labs and eClinical solutions

Accounts Payable Analyst

Full-TimePosted on 10/1/2026
No salary listed
Mid
Bachelor's
Hyderabad, Telangana, India
In Person

About the job

Requirements
  • Three to five years of relevant experience in payment processing, quality checking, and expense review.
  • A bachelor's degree with finance or accounting as a major is preferred.
  • Fluent English.
  • High accuracy when processing financial information and maintaining confidentiality.
  • A team-oriented approach, a continuous-improvement and critical mindset, and solid verbal and nonverbal communication skills.
Responsibilities
  • Process vendor payments, perform quality checks and vendor reconciliations, and handle day-to-day accounts payable activities.
  • Index invoices and ensure they are processed in the enterprise resource planning system.
  • Index and timely action help-desk queries received from internal and external parties.
  • Help the bank reconciliation team resolve open items from accounts payable payments.
  • Update vendor master data with proper supporting documents and in accordance with company policies, and create new vendor records in the vendor master database.
  • Review invoice coding and other invoice information as a quality checker after data entry.
  • Process weekly and ad hoc payments, create settlement runs, and communicate them to Treasury for approval.
  • Reconcile vendor accounts and work with vendors to resolve vendor statement reconciliation issues.
  • Work with Procurement to resolve purchase-order-related issues.
  • Review employee expense reimbursement reports created in Workday and credit-card expenses to ensure spending complies with company policy.
  • Maintain records and reports related to the accounts payable subledger and payments.
  • Ensure vendors properly apply payments according to remittance advices generated from payment runs.
  • Support period close by ensuring invoices are processed before close.
  • Provide requested documents and reports during audits.
  • Carry out other reasonable duties as requested.

About the company

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Perceptive Discovery launched α-Sight in April 2026 with MH3D, targeting oncology radioligands.
  • January 2026 brought $15 million for At-211 infrastructure across U.S. and U.K. sites.
  • April 2026 Trialzen and Kayentis alliances broaden Perceptive eClinical's commercialization and integration reach.

What critics are saying

  • Palantir's 2026 lawsuit against Percepta AI highlights talent-poaching and confidentiality vulnerability.
  • WCG and other imaging consolidators keep compressing Perceptive's core-lab pricing power.
  • If Perceptive misses alpha-imaging execution, CapVest's 2026 investment stops scaling returns.

What makes Perceptive unique

  • Perceptive spans discovery, imaging, and RTSM across one R&D workflow.
  • Its 2026 α-Sight partnership adds rare alpha-radiopharmaceutical imaging for Actinium-225 and Astatine-211.
  • Perceptive's 50-year lineage and 400-plus approvals signal embedded regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.